Zigakibart and Atrasentan Combination Therapy in Patients with IgAN: Design of a Phase 3b Randomized Controlled Trial (LUMINA IgAN) (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO07-SA; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The primary endpoint is proteinuria change from baseline to Week 36; secondary endpoints include the rate of proteinuria remission and incidence of adverse events. Upon completion of the double-blind period, patients will enter a 52-week open-label extension period."
Clinical • Combination therapy • P3 data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Glomerulonephritis • Heart Failure • IgA Nephropathy • Infectious Disease • Nephrology • Renal Disease • Vasculitis
|
|
Richard A. Lafayette; Jonathan Barratt; Kirk N. Campbell; Tobias B. Huber; Laura Kooienga; Tingting Li; Sayna Norouzi; Yusuke Suzuki; Sydney Tang; Hong Zhang; Malgorzata Gula; Tomasz Grzegorz Lawniczek; Hamid Moradi; M. Ines Neves; Vlado Perkovic
|